HDAC10 Gene

HDAC10 Gene

Overview

HDAC10 Gene

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">HDAC10 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>HDAC10</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>HDAC10</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=HDAC10" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">13 edges</a></td>
</tr>
</table>

HDAC10 (Histone Deacetylase 10) is a class IIb histone deacetylase encoded by the HDAC10 gene located on chromosome 22q13.33.[@osada2020] As a member of the histone deacetylase family, HDAC10 plays critical roles in epigenetic regulation by removing acetyl groups from lysine residues on histones and numerous non-histone proteins. Unlike other class II HDACs, HDAC10 demonstrates unique dual localization to both cytoplasm and nucleus, enabling it to participate in diverse cellular processes including transcriptional regulation, autophagy, DNA damage repair, and immune response modulation.

In the context of neurodegenerative diseases, HDAC10 has emerged as a significant player due to its central role in regulating autophagy—a critical cellular process for clearing misfolded proteins, damaged organelles, and toxic aggregates that accumulate in Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders. HDAC10 activity modulates the autophagy-lysosomal pathway, and altered HDAC10 expression has been documented in post-mortem brain tissue from AD and PD patients, as well as in various animal models of neurodegeneration.

Beyond autophagy, HDAC10 influences neuroinflammation through epigenetic regulation of cytokine and chemokine expression, contributes to neuronal survival through modulation of stress response pathways, and participates in synaptic plasticity mechanisms underlying learning and memory. These diverse functions position HDAC10 as both a potential biomarker for neurodegenerative disease progression and a promising therapeutic target for drug development.

The gene is expressed ubiquitously in human tissues with particularly high expression in liver, kidney, heart, and brain. In the central nervous system, HDAC10 is expressed in both neurons and glia, with astrocytic and microglial expression particularly relevant to understanding its role in neuroinflammation. The enzyme's unique structural features, including an N-terminal catalytic domain and a C-terminal leucine-rich repeat domain, distinguish it from other HDAC family members and contribute to its specific biological functions.

Gene Structure and Evolution

Genomic Organization

The human HDAC10 gene spans approximately 38 kb on chromosome 22q13.33 and consists of 16 exons. The gene encodes a protein of 669 amino acids with a molecular weight of approximately 78 kDa. Alternative splicing generates multiple HDAC10 isoforms, including a catalytically active full-length isoform and truncated variants with altered subcellular localization and function.

Key structural features include:

• N-terminal catalytic domain (aa 1-370): Contains the active site residues required for histone deacetylase activity
• Nuclear export signal (NES): Located at residues 85-95, mediating cytoplasmic localization
• Leucine-rich repeat (LRR) domain (aa 400-520): Unique among class II HDACs, involved in protein-protein interactions
• C-terminal domain: Contains additional regulatory sequences including phosphorylation sites

Evolution

HDAC10 is evolutionarily conserved across vertebrates, with orthologs identified in mammals, birds, reptiles, and teleost fish. The LRR domain appears to be a relatively recent addition during evolution, distinguishing HDAC10 from other class II HDACs and potentially enabling novel protein interaction networks. The enzyme shares common ancestry with HDAC6 (another class IIb member) but has diverged significantly in terms of tissue expression patterns and biological functions.

Protein Structure and Catalytic Mechanism

Structure

HDAC10 adopts a multi-domain architecture that underlies its unique functional properties:

Catalytic Domain:

• Contains a zinc-binding active site with the motif HXHXXG (residues 144-149)
• Forms a hydrophobic pocket that accommodates acetyl-lysine side chains
• Requires zinc ion (Zn²⁺) at the active site for catalysis
• Demonstrates broader substrate specificity than class I HDACs

• Composed of 12 LRR motifs forming a solenoid structure
• Mediates interactions with specific protein partners
• Contributes to substrate recognition and enzyme localization
• Unique to HDAC10 among human HDACs

• Multiple phosphorylation sites (Ser-232, Ser-876) affect activity and localization
• Nuclear export signal enables cytoplasmic shuttling
• Nuclear localization signal enables nuclear import

Catalytic Mechanism

HDAC10 catalyzes the removal of acetyl groups from ε-amino groups of lysine residues through a mechanism involving:

The reaction requires zinc ion coordination and is inhibited by HDAC inhibitors (HDACi) such as trichostatin A (TSA), vorinostat (SAHA), and panobinostat.

Expression and Localization

Tissue Distribution

HDAC10 demonstrates wide tissue distribution with highest expression in:

• Liver (hepatocytes)
• Kidney (proximal tubules)
• Heart (cardiac myocytes)
• Brain (neurons and glia)
• Lung (alveolar epithelium)
• Adrenal gland

• Cerebral cortex (layers II-VI, particularly layer 5 pyramidal neurons)
• Hippocampus (CA1-CA3 pyramidal cells, dentate granule cells)
• Cerebellum (Purkinje cells, granular layer)
• Basal ganglia (striatal medium spiny neurons)
• Brainstem (various nuclei)

Subcellular Localization

HDAC10 exhibits dynamic subcellular localization:

• Cytoplasmic: Predominant in most cell types; associated with vesicles and cytoskeletal elements
• Nuclear: Shuttles between cytoplasm and nucleus; nuclear import/export regulated by signaling
• Organelle-associated: Present in lysosomes and autophagosomes, enabling direct regulation of autophagy

• Phosphorylation status (Ser-232 phosphorylation promotes nuclear export)
• Cell cycle stage
• Cellular stress conditions
• Pathological states (neurodegeneration alters localization)

Biological Functions

Autophagy Regulation

HDAC10 serves as a key regulator of autophagy, a cellular process essential for maintaining protein homeostasis and cellular health:

Positive regulation of autophagy:

• Deacetylates key autophagy proteins including LC3, Atg5, and Atg7
• Enhances autophagosome formation through transcriptional regulation of autophagy genes
• Promotes fusion of autophagosomes with lysosomes
• Facilitates selective autophagy of damaged mitochondria (mitophagy)

• Regulates the PI3K-Akt-mTOR signaling pathway which controls autophagy initiation
• Modulates AMPK activation, which senses energy status and activates autophagy
• Interacts with the autophagy initiation complex through deacetylation of Beclin-1

• Impairment of autophagy contributes to accumulation of toxic protein aggregates (Aβ, tau, α-synuclein)
• HDAC10 expression is reduced in AD brains, correlating with impaired autophagy
• Enhancing HDAC10 activity in models reduces aggregate burden and improves neuronal survival

Epigenetic Regulation

As a histone deacetylase, HDAC10 contributes to epigenetic regulation through:

Histone modification:

• Removes acetyl groups from histone H3 and H4 tails
• Promotes chromatin condensation and transcriptional repression
• Regulates expression of genes involved in neuronal function, survival, and plasticity

• Deacetylates transcription factors including p53, NF-κB, and HIF-1α
• Modifies signaling molecules involved in neuronal homeostasis
• Regulates metabolic enzymes through acetylation status

• Represses pro-inflammatory gene expression (cytokines, chemokines)
• Suppresses apoptotic gene programs
• Promotes expression of neurotrophic factors (BDNF, GDNF)

Neuroinflammation

HDAC10 plays a significant role in modulating neuroinflammation:

Anti-inflammatory actions:

• Deacetylates NF-κB, reducing its transcriptional activity and pro-inflammatory target gene expression
• Suppresses NLRP3 inflammasome activation
• Reduces expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS)

• Modulates microglial activation state (M1/M2 polarization)
• Affects T-cell differentiation and function
• Influences astrocyte inflammatory responses

• HDAC10 inhibition may have anti-inflammatory effects in neurodegenerative contexts
• Selective HDAC10 modulators could reduce neuroinflammation without global HDAC inhibition side effects

DNA Damage Response

HDAC10 participates in DNA damage repair:

• Deacetylates DNA repair proteins including Ku70/Ku80
• Facilitates non-homologous end joining (NHEJ) repair
• Contributes to checkpoint activation following DNA damage
• Neurons, which are post-mitotic, rely heavily on NHEJ; HDAC10 supports genome integrity

Role in Neurodegenerative Diseases

Alzheimer's Disease

HDAC10 alterations in AD include:

Expression changes:

• HDAC10 mRNA and protein levels are elevated in AD prefrontal cortex and hippocampus
• This elevation correlates with disease severity
• Astrocytic HDAC10 shows particularly pronounced upregulation

• Impaired autophagy leads to Aβ accumulation and reduced Aβ clearance
• Tau pathology is exacerbated by reduced autophagic degradation of hyperphosphorylated tau
• Neuroinflammation is amplified through enhanced NF-κB activity

• HDAC10 inhibitors (including selective compounds under development) may enhance autophagy
• Combination approaches: HDAC10 modulation + current AD therapeutics
• Potential for disease-modifying effects through enhanced protein clearance

Parkinson's Disease

HDAC10 in PD models and patient tissue:

Pathological changes:

• Reduced HDAC10 expression in substantia nigra dopaminergic neurons
• This reduction correlates with impaired mitophagy and mitochondrial dysfunction
• Accumulation of damaged mitochondria contributes to neuronal death

• PINK1/Parkin-mediated mitophagy is regulated by HDAC10
• α-Synuclein aggregation is accelerated when autophagic clearance is impaired
• HDAC10 protects against rotenone and MPTP toxicity in cellular models

• HDAC10 activators could enhance mitophagy in PD
• Protecting dopaminergic neurons through improved protein and mitochondrial quality control

Amyotrophic Lateral Sclerosis (ALS)

HDAC10 alterations in ALS:

• HDAC10 expression is increased in spinal cord motor neurons of ALS patients
• Mutant SOD1 and TDP-43 pathology impairs autophagy
• HDAC10 modulation may help clear protein aggregates in motor neurons

Huntington's Disease

In HD models:

• HDAC10 contributes to transcriptional dysregulation through histone hyperacetylation
• Autophagy impairment exacerbates mutant huntingtin aggregation
• HDAC inhibition shows beneficial effects in HD models, partly through HDAC10 effects

Therapeutic Implications

HDAC Inhibitors

Current HDAC inhibitors have limitations:

Broad-spectrum limitations:

• First-generation HDACi (vorinostat, panobinostat) inhibit multiple HDAC isoforms
• Side effects include fatigue, thrombocytopenia, gastrointestinal toxicity
• Limited brain penetration reduces efficacy for neurodegenerative diseases

• Development of selective HDAC10 inhibitors is ongoing
• Phenylbutyrate and valproic acid have some HDAC10 activity
• Next-generation compounds aim for better selectivity

Therapeutic Strategies

Autophagy enhancement:

• HDAC10 activators to boost autophagic clearance
• Combined approaches: HDAC10 activation + autophagy inducers
• Substrate-specific enhancement (e.g., targeting Aβ or α-synuclein)

• Selective HDAC10 modulation reduces neuroinflammation
• May be combined with current anti-inflammatory approaches

• HDAC10 inhibition or modulation may enhance memory formation
• Requires careful balancing of epigenetic effects

Drug Development

Current HDAC10-targeted drug development:

Selective inhibitors:

• Several selective HDAC10 inhibitors in preclinical development
• Novel scaffolds with improved brain penetration
• Structure-activity relationship optimization

• Combined HDAC10/HDAC6 inhibitors for synergistic effects
• Integration with other therapeutic modalities

• Existing HDAC inhibitors with HDAC10 activity being evaluated
• FDA-approved compounds (e.g., valproic acid) have HDAC10 effects

Interaction Partners

HDAC10 interacts with numerous proteins:

Direct protein partners:

• HDAC6: Forms heterodimers, coordinates cellular stress responses
• Atg7: Autophagy protein, HDAC10 deacetylates this enzyme
• p53: Tumor suppressor, HDAC10 modulates its activity
• NF-κB (p65): Transcription factor, HDAC10 deacetylates and inhibits
• HIF-1α: Hypoxia-inducible factor, HDAC10 regulates its stability

• BCR (B-cell receptor) signaling complex
• TRAIL (TNF-related apoptosis-inducing ligand) pathway
• Interferon signaling components
• Metabolic enzymes (PKM2, LDHA)

Research Tools and Models

Experimental Systems

Cell lines:

• HEK293, HeLa: Standard biochemical studies
• SH-SY5Y: Neuronal differentiation, PD models
• PC12: Neuronal differentiation, neurotrophic factor studies
• Primary neurons: Cortical, hippocampal, mesencephalic
• iPSC-derived neurons: Patient-specific models

• HDAC10 knockout mice: Viable, with subtle phenotypes
• Transgenic models: HDAC10 overexpression or mutant forms
• Disease models: APP/PS1 (AD), α-synuclein transgenic (PD), SOD1 (ALS)

Detection Methods

• Activity assays: Fluorogenic substrates, HDAC activity measurements
• Western blot: HDAC10 protein detection with specific antibodies
• Immunohistochemistry: Localization in tissue sections
• qPCR: mRNA expression analysis
• RNA-seq: Transcriptomic profiling

Future Directions

Key research priorities include:

External Resources

• [NCBI Gene: HDAC10](https://www.ncbi.nlm.nih.gov/gene/83933)
• [UniProt: HDAC10](https://www.uniprot.org/uniprot/Q969S8)
• [Allen Brain Atlas: HDAC10 expression](https://brain-map.org/)
• [PubMed: HDAC10 neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=HDAC10+neurodegeneration)

Summary

HDAC10 (Histone Deacetylase 10) is a class IIb histone deacetylase with unique structural features including a leucine-rich repeat domain and dual nucleocytoplasmic localization. In the nervous system, HDAC10 plays critical roles in regulating autophagy, neuroinflammation, gene expression, and neuronal survival. Altered HDAC10 expression is implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, making it a promising therapeutic target. While broad-spectrum HDAC inhibitors have shown some benefit in neurodegenerative disease models, selective modulation of HDAC10 offers the potential for more targeted therapy with fewer side effects. Ongoing drug development aims to produce selective HDAC10 activators or inhibitors depending on the therapeutic context, with potential applications in enhancing protein clearance, reducing neuroinflammation, and protecting neuronal function.

References

See Also

• [Riluzole ALS Trials](/wiki/clinical-trials-riluzole-als) — therapeutic_target
• [DNMT3A Gene](/wiki/genes-dnmt3a) — activates
• [EGF Gene](/wiki/genes-egf) — therapeutic_target
• [EGFR Protein](/wiki/proteins-egfr) — therapeutic_target
• [Epigenetic Therapies for Neurodegeneration](/wiki/therapeutics-epigenetic-therapies-neurodegeneration) — activates
• [HDAC1 Gene](/wiki/genes-hdac1) — activates

Pathway Diagram

The following diagram shows the key molecular relationships involving HDAC10 Gene discovered through SciDEX knowledge graph analysis: